You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Mar 9, 2026; less than a full year is stored.
XFLH Capital Corporation signed a non-binding letter of intent with Renogen Biolab Inc. for a proposed business combination, with both parties committed to good-faith negotiations of definitive agreements and due diligence.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XFLH
this stock
XFLH Capital Corp
|
$141.11M | — | — | — | 0.0% |
|
VYLR
Vylor Inc.
|
$48.09B | — | — | — | 2.1% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$652.61M | +3.5% | — | — | 0.0% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$606.10M | +3.4% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
XFLH Capital Corporation signed a non-binding letter of intent with Renogen Biolab Inc. for a proposed business combination, with both parties committed to good-faith negotiations of definitive agreements and due diligence.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XFLH | +0.5% | +0.6% | +2.9% | +0.5% | — |
| SPY | +3.3% | -1.9% | +1.5% | +0.2% | +11.0% |
| vs SPY | -2.8% | +2.5% | +1.4% | +0.3% | — |
